

Supplementary Table 3

Individual biomarker group comparisons (Wilcoxon test)

	Healthy controls (N=19) Median pg/mL (IQR)	<i>Pk</i> -infected patients (N=19) Median pg/mL (IQR)	Crude P value	Corrected* P value
αSyn	863.4 (259.9)	2,177.8 (392.4)	<0.0001	<0.0001
APP	36,082.0 (25,945.0)	17,701 (12,728.0)	0.0010	0.05
Aβ₍₁₋₄₂₎	0.2 (1.2)	1.6 (0.9)	0.08	1.00
BDNF	1,516.2 (1,454.1)	146.2 (115.8)	<0.0001	<0.0001
CaBD	1,807.0 (179.0)	1,151.1 (221.0)	<0.0001	<0.0001
CNTN1	18,191.0 (4,890.0)	6,179.7 (2,615.6)	<0.0001	<0.0001
ENO2/NSE	54,324.0 (21,601.0)	1,094,366.0 (1,382,298.0)	0.0010	0.05
Fetuin A	176,390,803.0 (38,746,703.0)	154,460,943.0 (47,209,645.0)	0.0462	1.00
GFAP	78.1 (45.8)	29.9 (25.3)	<0.0001	0.0013
KLK6	2,319.5 (915.0)	1,072.4 (788.7)	0.0003	0.0126
Lipocalin 2	547,608.0 (149,670.0)	619,695.0 (94,135.0)	0.05	1.00
NCAM-1	107,813.0 (38,204.0)	70,203.0 (8,851.0)	<0.0001	<0.0001
NfL	8.1 (4.4)	6.3 (5.8)	0.21	1.00
NGF-β	0.9 (1.2)	1.7 (1.5)	0.0203	1.00
NRGN	22.4 (11.1)	241.4 (763.1)	<0.0001	0.0022
Park7	71,436.0 (61,372.0)	161,810.0 (146,171.0)	<0.0001	0.0006
S100B	27.3 (0.0)	1,282.2 (1,777.2)	<0.0001	<0.0001
Tau total	0.6 (0.6)	3.7 (5.0)	<0.0001	0.0007
TDP-43	5,344.3 (5,806.0)	67,143.0 (90,407.0)	<0.0001	0.0050
UCHL-1	49.3 (45.4)	336.6 (184.1)	<0.0001	<0.0001
YKL40	29,591.0 (24,732.0)	58,674.0 (33,187.0)	0.0020	0.10

*Bonferroni correction for multiple comparisons.

		Healthy controls (N=19) Median pg/mL (IQR)	<i>Pk</i> -infected patients (N=19) Median pg/mL (IQR)	Crude P value	Corrected* P value	
Biomarkers of infection and immune activation	Pro-inflammatory cytokines	CRP	668,496.0 (308,499.0)	477,838.0 (235,914.0)	0.0005	0.0280
		GM-CSF	23.8 (10.0)	21.52 (8.7)	0.24	1.00
		IFNγ	101.4 (11.8)	104.8 (46.3)	0.73	1.00
		IL-1α	49.0 (46.4)	46.0 (21.2)	0.29	1.00
		IL-1β	24.7 (7.2)	40.0 (17.9)	0.0027	0.14
		IL-2	34.8 (28.7)	33.1 (62.5)	0.53	1.00
		IL-6	11.5 (2.6)	21.7 (19.2)	0.0013	0.06
		IL-8	319.7 (599.0)	254.6 (2,353.2)	0.82	1.00
		IL-17A	29.2 (6.1)	22.2 (8.3)	0.0081	0.41
		MIF	384.6 (315.8)	630.7 (321.2)	0.0022	0.11
		MPO	1,571,073.0 (869,998.0)	3,176,104.0 (919,812.0)	0.0006	0.0314
	Anti-inflammatory	TNF-α	16.2 (5.7)	13.7 (2.3)	0.0393	1.00
		IL-1RA	6,736.0 (2,506.0)	35,639.0 (21,569.0)	<0.0001	<0.0001
		IL-4	165.1 (12.2)	159.8 (35.1)	0.44	1.00
	Chemokines	IL-10	8.0 (1.3)	48.6 (116.0)	<0.0001	<0.0001
		CCL2	380.8 (326.0)	160.9 (219.4)	0.0075	0.38
		CCL4	781.8 (250.0)	526.3 (47.7)	<0.0001	0.0002
		CCL5	158,730.0 (96,050.0)	17,650.0 (27,045.0)	<0.0001	<0.0001
	Other	CCL18	76,800.0 (37,565.0)	76,703.9 (73,970.5)	0.89	1.00
OPN		12,981.0 (11,051.0)	5,057.0 (3,291.0)	0.0033	0.17	
RAGE		7,206.0 (2,599.0)	4,797.0 (1,840.0)	<0.0001	0.0025	

*Bonferroni correction for multiple comparisons.

	Healthy controls (N=19) Median pg/mL (IQR)	<i>Pk</i> -infected patients (N=19) Median pg/mL (IQR)	Crude P value	Corrected* P value
	Ang-1	51,807.0 (23,226.0)	1,547.8 (1,633.8)	<0.0001
Ang-2	3,187.0 (1,277.0)	2,561.7 (1,365.2)	0.0471	1.00
Ang-2/Ang-1 ratio	0.1 (0.1)	1.5 (0.6)	<0.0001	<0.0001
BMP-9	205.9 (193.2)	3.6 (2.3)	<0.0001	<0.0001
ICAM-1	705,782.0 (710,688.0)	832,537.0 (324,397.0)	0.98	1.00
PDGF AA	3,864.0 (689.0)	552.6 (346.2)	<0.0001	<0.0001
PDGF BB	18,495.0 (7,646.0)	1,385.7 (2,055.8)	<0.0001	<0.0001
Serpin E1	932,450.0 (468,184.0)	183,488.0 (103,411.0)	<0.0001	<0.0001
VCAM-1	698,022.0 (419,633.0)	1,673,430.0 (2,154,222.0)	<0.0001	0.0001
VEGF	147.3 (81.2)	178.9 (118.7)	0.26	1.00
vWF	6,716.8 (8,770.7)	6,173.0 (3,737.2)	0.20	1.00

*Bonferroni correction for multiple comparisons.

Biomarkers of brain alterations or cerebral injury:

αSyn: alpha-Synuclein; **APP**: amyloid-beta precursor protein; **Aβ₁₋₄₂**: amyloid beta (1-42); **BDNF**: brain-derived neurotrophic factor; **CaBP**: Calbindin D; **CNTN1**: contactin-1; **CSF**: cerebrospinal fluid; **ENO2 / NSE**: Enolase 2 / Neuron-specific Enolase; **GFAP**: glial fibrillary acidic protein; **KLK6**: kallikrein 6 / neurosin; **NCAM-1**: neural cell adhesion molecule; **Lipocalin-2**: neutrophil gelatinase-associated lipocalin; **NGF-β**: nerve growth factor beta; **NfL**: neurofilament light chain; **NRGN**: neurogranin; **Park7**: Parkinsonism-associated deglycase; **S100B**: S100 calcium-binding protein β; **TDP-43**: TAR DNA-binding protein 43; **Tau**: total Tau protein; **UCH-L1**: ubiquitin carboxy-terminal hydrolase L1; **YKL40**: Chitinase-3-like protein 1.

Biomarkers of infection and immune activation:

CCL2: chemokine (C-C motif) ligand 2; **CCL4**: chemokine (C-C motif) ligand 4; **CCL5**: chemokine (C-C motif) ligand 5; **CCL18**: chemokine (C-C motif) ligand 18; **CRP**: C-reactive protein; **GM-CSF**: granulocyte-macrophage colony-stimulating factor; **IFN-γ**: interferon gamma; **IL-1α**: interleukin 1 alpha; **IL-1β**: interleukin 1 beta; **IL-1RA**: interleukin 1RA; **IL-2**: interleukin 2; **IL-4**: interleukin 4; **IL-6**: interleukin 6; **IL-8**: interleukin 8; **IL-10**: interleukin 10; **IL-17A**: interleukin 17; **MIF**: migration inhibitory factor; **MPO**: myeloperoxidase; **OPN**: osteopontin; **RAGE**: receptor for advanced glycation end-products; **TNF-α**: tumour Necrosis Factor alpha.

Vascular biomarkers:

Ang-1: angiotensin-1; **Ang-2**: angiotensin-2; **Ang-2/Ang-1**: ratio between Ang-2 and Ang-1; **BMP-9**: bone morphogenetic protein 9; **ICAM-1**: intercellular adhesion molecule 1; **PDGF-AA**: platelet-derived growth factor AA; **PDGF-BB**: platelet-derived growth factor BB; **Serpin E1**: Serine Proteinase Inhibitor-clade E1; **VCAM-1**: vascular cell adhesion molecule; **VEGF**: vascular endothelial growth factor; **vWF-A2**: von Willebrand Factor (A2 domain). *Pk*: *Plasmodium knowlesi*; **IQR**: interquartile range.